All Photos(1)

Documents

Y0001480

Sulfadiazine for identification of impurity F

Name: Sulfadiazine for identification of impurity F
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Sulfadiazine, 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide, N¹-(Pyrimidin-2-yl)sulfanilamide

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₀H₁₀N₄O₂S

CAS Number:

68-35-9

Molecular Weight:

250.28

Beilstein:

6733588

MDL number:

MFCD00006065

UNSPSC Code:

41116107

PubChem Substance ID:

329831448

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

sulfadiazine

manufacturer/tradename

EDQM

mp

253 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2

InChI

1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

InChI key

SEEPANYCNGTZFQ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sulfadiazine for identification of impurity F EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

Signal Word

Warning

Hazard Statements

H302,H361d,H411

Precautionary Statements

P202 - P264 - P273 - P280 - P301 + P312 - P308 + P313

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Repr. 2

WGK

WGK 2

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

[Acute kidney failure caused by sulfadiazine stones. A complication of the therapy of toxoplasmosis in AIDS].

U Kronawitter et al.

Deutsche medizinische Wochenschrift (1946), 118(46), 1683-1686 (1993-11-19)

A 45-year-old man with AIDS was treated for a recurrence of cerebral toxoplasmosis with sulphadiazine, 4 g, and pyrimethamine, 75 mg, daily. Owing to a lack of appetite and dysphagia he drank rather little water during the first week of

Silver sulfadiazine: an antibacterial agent for topical use in burns. A review of the literature.

S Hoffmann

Scandinavian journal of plastic and reconstructive surgery, 18(1), 119-126 (1984-01-01)

Topical antibacterial treatment is of major importance in the burn patient. Silver sulfadiazine is an effective agent with low toxicity and few side effects. Deposition of silver in tissues, and absorption of sulfadiazine are both minimal. Present and future problems

Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations.

L M Upton et al.

Antimicrobial agents and chemotherapy, 59(1), 490-497 (2014-11-12)

To achieve malarial elimination, we must employ interventions that reduce the exposure of human populations to infectious mosquitoes. To this end, numerous antimalarial drugs are under assessment in a variety of transmission-blocking assays which fail to measure the single crucial

Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome.

D I Simon et al.

Archives of internal medicine, 150(11), 2379-2384 (1990-11-01)

Toxoplasma gondii encephalitis is an important opportunistic infection in the acquired immunodeficiency syndrome, estimated to occur in 20,000 to 40,000 patients with acquired immunodeficiency syndrome in the United States by 1991. The combination of sulfadiazine and pyrimethamine is regarded as

Sulfadiazine-induced nephrolithiasis in children.

Charlotte Catalano-Pons et al.

Pediatric nephrology (Berlin, Germany), 19(8), 928-931 (2004-06-19)

Sulfadiazine-associated urinary calculi have been described in HIV-positive adult patients but rarely in children. We report two pediatric cases of sulfadiazine-induced nephrolithiasis and review 45 adult cases from the literature. One had a hyper-IgM syndrome and was treated with sulfadiazine

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service